Physician profile
James Drost
NPI 1922014133
$3,357.20
in general payments reported to CMS, 2019-2025
25 companies · $198 in 2025
The $198 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $525 · 2020: $171 · 2021: $826 · 2022: $504 · 2023: $561 · 2024: $572 · 2025: $198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,331.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,331.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $702.11 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $282.74 | 2019-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $267.28 | 2019-2023 | Belsomra, Lagevrio, Steglatro |
| Abbvie INC. | $244.33 | 2021-2024 | Ubrelvy, Qulipta |
| Otsuka America Pharmaceutical, INC. | $229.27 | 2019-2025 | Rexulti |
| Lilly USA, LLC | $224.12 | 2020-2025 | Mounjaro, Zepbound |
| Astellas Pharma US INC | $204.82 | 2019-2024 | Veozah |
| Amgen INC. | $165.82 | 2019-2022 | |
| Pfizer INC. | $147.60 | 2019-2024 | |
| Nestle Healthcare Nutrition INC. | $132.06 | 2021-2022 | |
| Philips North America LLC | $110.49 | 2021-2023 | |
| Astrazeneca Pharmaceuticals Lp | $98.23 | 2019-2024 | Airsupra, Farxiga |
| Exact Sciences Corporation | $92.18 | 2023-2024 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $77.90 | 2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $53.58 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $51.31 | 2019-2021 | |
| Paratek Pharmaceuticals, INC. | $45.53 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $34.75 | 2021-2022 | |
| Vertex Pharmaceuticals Incorporated | $32.79 | 2025 | |
| Novartis Pharmaceuticals Corporation | $32.62 | 2019-2021 | |
| Abbott Laboratories | $31.61 | 2024 | Freestyle Libre 3 |
| Allergan, INC. | $31.41 | 2019 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $31.26 | 2022 | |
| Tactile Systems Technology INC | $22.00 | 2024 | Flexitouch Plus, Entre Plus |
| Genentech USA, INC. | $11.39 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Drost listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.